Cardiodynamics' --CDIC-- CEO, Michael K. Perry, Interviewed On Three Leading Online Investment Sites; CEOcast.com, Wallstreetreporter.com, Radiowallstreet.com.

Business Editors and Health/Medical Writers

SAN DIEGO--(BW HealthWire)--July 14, 2000

CardioDynamics International Corporation (Nasdaq NM:CDIC), manufacturer of BioZ(R) noninvasive digital cardiac function monitoring systems, announced that Michael K. Perry, chief executive officer, was interviewed by three leading online investment sites. The interviews cover the company's recent joint technology agreement with GE Marquette Medical Systems and FDA 510(k) Clearance for BioZ.pc(TM).

These interviews can be heard online at www.ceocast.com, www.wallstreetreporter.com, and www.radiowallstreet.com. Links to these interviews are on the company's Investor News section at www.cdic.com. The interviews are intended to familiarize individual investors and investment firms with CardioDynamics, while giving them pertinent information on company background, management team, market opportunity and the products that are the driving forces behind the company.

CEOcast.com is organized by industry. Its analysts average over 15 years experience covering and evaluating Wall Street's leading companies. Wallstreetreporter.com offers in-depth interviews that are geared towards sophisticated investors who demand an unbiased, unscripted, first-hand perspective that enables them to make informed investment decisions. Radiowallstreet.com, part of the Investor Broadcast Network, gives all investors access to the inner circle of corporate executives and industry thought leaders.

CardioDynamics, with headquarters in San Diego, is a medical technology and information solutions company committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, the BioZ(R) System and BioZ.com(R), utilize proprietary BioZ Impedance Cardiography (ICG) technology to noninvasively provide medical professionals with hemodynamic data not previously available in the physician's office and many hospital settings. Just as Electrocardiography (ECG) measures the heart's electrical characteristics, ICG makes it possible to noninvasively measure the heart's mechanical (blood flow) characteristics. Physicians around the world are currently using the BioZ products, including major medical centers such as the Mayo Clinic (Rochester), Stanford University School of Medicine (Palo Alto), University of California San Francisco (San Francisco), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $5 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(R) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1999 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.